NASDAQ:GNLX
Genelux Corporation Stock News
$2.28
+0.220 (+10.68%)
At Close: Jun 24, 2024
WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten o
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
04:01pm, Thursday, 23'rd May 2024
WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwr
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
04:25pm, Thursday, 09'th May 2024
WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
10:36am, Friday, 26'th Apr 2024
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
10:36am, Tuesday, 23'rd Apr 2024
The heavy selling pressure might have exhausted for Genelux Corporation (GNLX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
10:35am, Friday, 05'th Apr 2024
Genelux Corporation (GNLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
01:02pm, Thursday, 04'th Apr 2024
Genelux Corporation (GNLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Monday, 01'st Apr 2024
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiati
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
07:00am, Monday, 27'th Nov 2023
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
05:50pm, Tuesday, 14'th Nov 2023
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalent
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 14'th Sep 2023
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company'
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
04:01pm, Thursday, 07'th Sep 2023
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairma
Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing
01:56pm, Wednesday, 30'th Aug 2023
Genelux has already initiated a phase 3 study known as OnPrime/GOG-3076, which is using the Olvi-Vec combination therapy to treat patients with platinum resistant/refractory ovarian cancer. In the pha
Genelux Corporation Announces New Chief Financial Officer
07:00am, Monday, 28'th Aug 2023
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
07:00am, Monday, 14'th Aug 2023
- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two private
